Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia

Abstract

Background: Acute cardiovascular (CV) events have been evaluated in patients with specific comorbidities but have not focused on patients with hyperlipidemia or on the their long-term costs. Objectives: To evaluate incidence of CV events, costs, and resource utilization among patients with hyperlipidemia and baseline risk of CV disease (CVD). Methods: Patients (age 18 to 64 years) diagnosed with hyperlipidemia or using lipid-modifying medications were identified from administrative claims. Patients were categorized into 3 cohorts based on pre-index clinical characteristics-secondary prevention (SP; history of CV event, n = 15 613); high risk (HR; CVD, n = 47 600); and primary prevention (PP; no CV event history or CVD, n = 60 637)-and followed up to 2 years after the CV event.Results: During follow-up, ≥1 new CV event occurred in 43.0% of the SP cohort, 33.9% of HR, and 20.9% of PP; and ≥3 new events occurred in 19.8% of the SP cohort, 12.9% of HR, and 5.5% of PP. Incremental total costs were $19 320 for SP, $20 003 for HR, and $17 650 for PP. Compared with patients with only 1 CV event, the mean 2-year cost was 30% higher in patients with 2 CV events and 48% higher in patients with 3 CV events. Only 50% of HR patients (with or without CV events) received statins. Conclusions: Patients with recurrent CV events had higher total health care costs during 24-month follow-up for each type of CV event. Total health care costs among patients with a CV event were higher for the initial as well as subsequent events. Statins and lipid-modifying medications were significantly underutilized in all cohorts, despite the presence of CVD.

Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context

“…Two US claims database Table 5. analyses 6,38 reported a 43% subsequent CV event risk over 2-3 years of follow-up for patients with a history of MI, stroke, UA, or revascularization. CV event risk was 49% over 2 years among a Swedish cohort of patients with a history of CVD 39 .…”

“…Atherosclerosis is the underlying cause of most clinical CV events 3 , including coronary heart disease (CHD), acute coronary syndromes (ACS) such as myocardial infarction (MI) or unstable angina (UA), peripheral artery disease (PAD), heart failure (HF), transient ischemic attack, ischemic stroke (IS), and CV-related death 1,4 . Recent studies have shown that 15%-43% (over 2-3 years) of patients with a primary CV event will experience a second CV event 5,6 .…”

Economic Burden of Hypercholesterolemia in the Russian Federation

“…В условиях демографического старения популяции в РФ общее число лиц с этими нарушениями The Economic Burden of Hypercholesterolemia in the RF Экономический ущерб от гиперхолестеринемии в РФ будет возрастать, увеличивая затраты системы здравоохранения и государства в целом. Затраты системы здравоохранения, ассоциированные с сердечно-сосудистыми событиями у лиц с ГХС, продемонстрированы в ряде исследований [11,12,43]. Так, португальские исследователи показали, что в ценах 2013 г. прямые затраты, ассоциированные с ГХС, составили €320 млн, а непрямые, связанные с выплатами по инвалидности -€198 млн [44].…”

A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia

“…Previous research has been valuable in demonstrating the great cost burden of CVEs [ 8 , 16 , 20 – 22 ], yet only one report specifically assessed cohorts of patients with hyperlipidemia. Given that adequate hyperlipidemia treatment lowers the risks associated with CVEs, it is important to obtain current cost estimates associated with CVEs.…”